Skip to main content
. 2023 Aug 30;11(8):e007118. doi: 10.1136/jitc-2023-007118

Figure 2.

Figure 2

Overall survival in Phase 1 and 2 treated patients by (A) prior number of therapy lines, (B) prior blinatumomab exposure, (C) prior inotuzumab exposure, and (D) prior alloSCT exposure. Kaplan-Meier estimates of the overall survival. alloSCT, allogeneic stem cell transplantation; mo, month; NE, not estimable; No, number; NR, not reached.